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a  b  s  t  r  a  c  t
Passiﬂora  alata Curtis,  Passiﬂoraceae,  is  a  liana  popularly  known  in  Brazil  as  ‘maracujá-doce’  that  has
been  used  for  treating  different  illnesses.  Its  leaves  are  described  in  the  Brazilian  Pharmacopoeia,  but
the  gastroprotective  activity  has  never  been  investigated.  In  the present  study  a freeze-dried  crude  60%
ethanol–water  extract  of  P.  alata  aerial  parts  was  prepared.  Total  ﬂavonoid  content,  expressed  as vitexin,
was 0.67%  ± 0.01. The  hemolytic  activity  was  32  units  for  P. alata,  using  Saponin  (Merck®)  as reference.  P.
alata  presented  EC50 of  1061.2  ±  8.5  g/ml  in  the  2,2-diphenyl-1-picryhydrazyl  assay  and  1076  ±  85  mol
Trolox/g  in  the  Oxygen  Radical  Absorbance  Capacity  assay.  P.  alata,  its  solvent  fractions  and  a P.  alata
nanopreparation  were  investigated  for gastroprotective  activity.  The  test  samples  exhibited  gastropro-
tective  activity on HCl/ethanol  induced  gastric  mucosal  lesions  in  rats.  P.  alata  at doses  of  100,  200  and
400  mg/kg,  using  the  necrotizing  agent  at 150  mmol/l,  inhibited  100%  of ulcer  formation  (compared  to the
negative  control),  while  lansoprazole  (30  mg/kg)  77%.  When  tested  against  a more  concentrated  necrotiz-ntioxidant
ing  agent  (300  mmol/l),  fractions  of  P. alata at 100  mg/kg  reduced  57% (n-hexane),  34%  (ethyl  acetate)  and
72% (aqueous  fraction)  the  ulcer  formation.  In this  assay,  lansoprazole  (30  mg/kg) inhibited  47%.  When
encapsulated,  P.  alata inhibited  ulcer  formation  at 55%, 94%  and 90%  for dosages  of 25, 50  and  100  mg/kg.
These  results  suggest  the potential  use  of P.  alata as  a gastroprotective  herbal  medicine.
ileira©  2015 Sociedade  Bras
ntroduction
Several Passiﬂora L., Passiﬂoraceae, species are used in the tra-
itional medicine around the world. In Europe and United States,
assiﬂora incarnata L. has been used for treating nervous rest-
essness, insomnia, hysteria, most of the times in combination
ith other sedative extracts. Its aerial parts are ofﬁcially listed as
lant drug in various Pharmacopeias. The predominant compound
lass in this species is C-glycosyl ﬂavones; harman alkaloids, when
resent, occur in trace amounts (Blumenthal, 1998; Gruenwald
t al., 2000; EMA, 2014).
This genus comprises more than 400 species distributed
hroughout tropical and subtropical areas, mainly from Central and
outhern America (Plotze et al., 2005). In Brazil, there are approx-
mately 140 species reported, from which 83 are endemic and 44
nly in São Paulo State (Bernacci et al., 2015).
Passiﬂora alata Curtis is an evergreen vine, which bears an edi-
le type of passion fruit, endemic from Brazil, occurring from the
∗ Corresponding author.
E-mail: elfriede@usp.br (E.M. Bacchi).
http://dx.doi.org/10.1016/j.bjp.2015.07.011
102-695X/© 2015 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editora de  Farmacognosia.  Published  by Elsevier  Editora  Ltda.  All  rights  reserved.
Amazon until the Atlantic Rain Forest (Bernacci et al., 2015). This
species is widely cultivated for its edible fruits, appreciated in the
local culinary (Lorenzi et al., 2006), and it has been used for treat-
ing different illnesses, e.g., nervous disturbs and gastric problems
(Petry et al., 2001; Duke, 2002; Gosmann et al., 2011; Noriega et al.,
2011). Due to its pharmacological relevance, it had been cited in
four editions of the Brazilian Pharmacopeia (Pharmacopeia dos
Estados Unidos do Brasil, 1926; Farmacopeia dos Estados Unidos
do Brasil, 1959; Farmacopeia Brasileira, 1977, 2010).
Most of the studies about the chemical composition of P. alata
leaves lead to the identiﬁcation of several C-glycosidic ﬂavonoids
(Ulubelen et al., 1982; Doyama et al., 2005; Müller et al., 2005)
and saponins (Reginatto et al., 2004; Birk et al., 2005). The anx-
iolytic activity from P. alata leaf extracts was proved in different
pharmacological assays and it has been related to these metabolite
classes (Oga et al., 1984; De-Paris et al., 2002; Reginatto et al., 2006;
Provensi et al., 2008; Klein et al., 2014). Besides the anxiolytic effect,
other biological activities have been detected in rodents, such as
anti-inﬂammatory (Vargas et al., 2007), and as anti-diabetic in type
1 diabetes mellitus (Colomeu et al., 2014).
Concerning safety issues, the P. alata leaf extracts had no effect
in female rat fertility (Amaral et al., 2001), but there was  some
 Ltda. All rights reserved.
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ndication of genotoxicity (Boeira et al., 2010), hepatotoxicity and
norexic activities in rodents (Braga et al., 2013).
Active compounds like ﬂavonoids, tannins and other gluco-
ides sometimes have good water solubility. However, they can
lso present low absorption, resulting in a loss of bioavailability
nd efﬁcacy. Others may  show poor water solubility and also have
bsorption issues. Nanostructured systems have the potential of
ontrolling the release or reducing the amount of active compounds
o obtain the desired efﬁcacy. They can also assist on directing the
olecule to its biological target (Bonifácio et al., 2014).
Poly(-caprolactone) nanocapsules are among the possibili-
ies when using nanotechnology in the development of herbal
edicines. The biodegradability and biocompatibility of this poly-
er  make its use favorable in pharmaceutics. These nanocapsules
ave a lipid core and may  change pharmaceutical and pharmaco-
ogical parameters of a drug, as prolonged release and enhanced
tability (Pohlmann, 2013).
Concerning antiulcer activity, epidemiological data estimates
hat at some point in their lives, 4–12% of adults might develop
 peptic ulcer (Leontiadis and Nyrén, 2014). The latest detailed
pidemiology consists of 2009 when Sung et al. reported that the
nnual incidence of peptic ulcer in the world varies from 0.10% to
.19%, and the prevalence from 0.12% to 1.5%. It means that tens of
illions of people worldwide have this disease, making it one of
he most relevant today.
Considering that most of the pharmacological research on P.
lata is focused on its central nervous system activity and that to
ate there are no scientiﬁc data concerning the antiulcer properties
f this species (Noriega et al., 2011), the present study was  car-
ied out to evaluate a possible gastroprotective activity of P. alata,
ased on the traditional use for gastric problems. In order to pro-
ose P. alata as an gastroprotective herbal product, we  assayed its
rude lyophilized extract, some solvent partition fractions and a
oly(-caprolactone) nanocapsules preparation.
aterials and methods
lant material
Aerial parts of Passiﬂora alata Curtis, Passiﬂoraceae, were pro-
ided by the Instituto Agronômico de Campinas from an Active
ermplasm Bank located in Monte Alegre do Sul, SP (750 m high).
he species was authenticated by Dr. Luís Carlos Bernacci. A
oucher specimen was deposited at the Instituto de Biociências’
erbarium, Universidade de São Paulo, with respective registration
umber VM01.
reparation of the extract and fractions
Aerial parts were cut, washed, and dried in an air circulation
ven at temperature below 50 ◦C for 72 h. After drying, the plant
aterial was ground in a rotatory cutter mill to obtain particles
f 0.5–1.0 mm.  The powdered material was percolated with 60 ◦GL
thanol in a proportion plant:solvent of 1:10 (w/v). After extraction,
he solvent was eliminated under vacuum in a rotatory evaporator
t 40–45 ◦C and the residual water was eliminated by freeze-drying,
ielding a brown-greenish powder. The freeze-dried crude P. alata
xtract (PA) had its total ﬂavonoids quantiﬁed accordingly the
uropean Pharmacopeia quality control method for P. incarnata L.
European Pharmacopoeia, 2011) and the results are expressed as
ercentage of vitexin. As P. alata is also known to contain saponins,
hich may  cause hemolysis when added to a suspension of blood,
he hemolytic activity of PA was determined according the World
ealth Organization methodology (WHO, 2011) by comparison
ith that of a reference Saponin (Merck®).rmacognosia 25 (2015) 407–412
PA was  fractioned from 10 g of the crude extract, partition-
ing between water and n-hexane, followed by ethyl acetate. Each
extraction was performed with 3 × 20 ml solvent. Each fraction was
separately concentrated under reduced pressure.
Nanoencapsulation
Nanoencapsulated extracts of PA were obtained by a solvent
displacement technique. Poly(-caprolactone) (PCL) (0.010 g) was
dissolved in 27 ml  of acetone, by stirring (200 rpm) for 40 min  at
40 ◦C (organic phase). A total of 0.333 g of capric/caprylic triacyl-
glyceride and 0.077 g of sorbitan monostearate (span 60) were
added to the organic phase. PA extract was  added after the polymer
dissolved and allowed to stir for 10 min  in the organic phase, after
this time the extract was  completely dissolved in the organic phase
(25, 50 and 100 mg  yielding 2.5; 5.0 and 10 mg/ml  concentrations).
The organic phase was  gently injected inside the aqueous solu-
tion (53 ml  of water) containing 0.070 g of polysorbate 80. Polymer
deposition at the interface of the solvents leaded to the instanta-
neous formation of a colloidal suspension. The organic solvent was
removed using reduced pressure in a rotary evaporator, and the
ﬁnal aqueous volume was  adjusted to 10 ml  with water.
Characterization of the encapsulated extract
The average particle size and the polydispersity index (PDI) were
measured by DLS (dynamic light scattering) using a Zetasizer ZN
particle size analyzer (Malvern Instruments, Southborough, UK)
equipped with vertically polarized light supplied by an argon-ion
laser. The Zeta potential was  also determined by DLS (Zetasizer ZN
particle size analyzer, Malvern Instruments, Southborough, UK). All
the measurements were determined from the mean values of three
experiments.
Antioxidant activity
One assay to determine P. alata antioxidant capacity was
scavenging of the 2,2-diphenyl-1-picryhydrazyl (DPPH) radical as
described by Mensor et al. (2001). The P. alata stock solution
(2.0 mg/ml  in ethanol) was  diluted in ethanol to concentrations of
0.125, 0.25, 0.5, 1.0 and 2.0 mg/ml. One milliliter of DPPH solution
was added to 2.5 ml  of the different concentrations of the extract
and the positive control. The 0.3 mmol/l DPPH (Sigma®) solution
was prepared in ethanol. Rutin was employed as a positive control
at concentrations of 3.125, 6.25, 12.5, 25 and 50 g/ml. Solutions
containing 1 ml  ethanol and 2.5 ml  of each extract were used as
blanks. The absorbance of samples, positive controls, and blanks at
518 nm was  determined after 30 min. The EC50 values were calcu-
lated by linear regression of plots where the abscissa represented
the concentration of tested plant extracts and the ordinate the aver-
age percent of antioxidant activity from three separate tests.
The ORAC (Oxygen Radical Absorbance Capacity) assay was  per-
formed in a microtiter plate reader according to Huang et al. (2002).
Brieﬂy, AAPH (2,2′-azobis[2-amidinopropane] dihydrochloride,
Sigma-Aldrich®) was  used as a peroxyl radical generator, Trolox
as a standard, and ﬂuorescein as a ﬂuorescent probe. Filters were
used to select an excitation wavelength of 485 nm and an emission
wavelength of 520 nm.  Twenty-ﬁve microlitres of diluted sample
(P. alata extract 0.039, 0.029, 0.023, 0.019 and 0.017 mg/ml), blank,
or Trolox calibration solution (6.25–100 mol/l) were mixed with
150 l ﬂuorescein (4 mol/l) and incubated for 30 min  at 37 ◦C
before injection of 25 l. AAPH (173 mmol/l) solution. The ﬂuo-
rescence was  measured every minute for 1 h. All samples were
analyzed in duplicate at three different dilutions. The ﬁnal ORAC
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alues were calculated using the net area under the decay curves.
he result is expressed as micromole Trolox equivalent/g of sample.
nimals
Female Wistar rats weighing 150–180 g from Faculdade de Ciên-
ias Farmacêuticas, Universidade de São Paulo, were housed in
tandard cages at room temperature (20 ± 3 ◦C) with 12 h dark/light
ycles. They were fastened for 12 h but allowed free access to water
efore the experimentation. Assays were carried out using 7–9 ani-
als per group, randomly divided. The research was  conducted in
ccordance with the internationally accepted principles for labo-
atory animal use and care, and the protocol for use of animals
as been approved by Comitê de Ética em Experimentac¸ ão Animal,
aculdade de Ciências Farmacêuticas, Universidade de São Paulo,
umber 132/2006.
astroprotective activity
The experiment was performed according to methodology
escribed by Mizui and Doteuchi (1983).
The solutions of PA and its fractions, plus the necrotizing agent
nd the control lansoprazole were freshly prepared before admin-
stration. Test solutions were administered by gavage (10 ml/kg)
t the following concentrations: PA 100, 200, 400 mg/kg body
eight (assay 1); PA Fractions, n-hexane, ethyl acetate and water,
00 mg/kg (assay 2); nanoencapsulated PA, 50 and 100 mg/kg
assay 3). Control rats received the vehicle (water), nanocapsules
ithout extract or lansoprazole (30 mg/kg) suspended in vehicle,
ame volume as test samples.
Thirty minutes after the administration of test samples, lesions
ere induced by administering by gavage an HCl solution in
thanol/water 60% (v/v) at doses of 10 ml/kg body weight. The
dministered HCl concentrations were 150 mmol/l for assay 1 and
00 mmol/l for assays 2 and 3. One hour later, the animals were
illed in a CO2 chamber. The stomachs were removed and opened
long the greater curvature to determine relative lesion area (RLA,
n %). The relative lesion area was determined as follows:
LA = (TLA × 100)
TA
,
here TLA = total lesion area (mm2), TA = total stomach area (mm2).
Albeit in the graphics the numbers were standardized as % of
esion area, we understand that % of inhibition facilitates under-
tanding. The latter describes a comparison between test and
egative control, bringing more meaning to these values. Now, the
ormula of % of inhibition was included and this relation is better
xplained.
 of inhibition = 100 −
(
% RLA of tested group
% RLA of negative control
)
× 100
tatistical analysis
The values were expressed as mean ± standard error of the mean
SEM). Statistical analysis was performed through ANOVA followed
y Tukey. Signiﬁcant differences were considered for p < 0.05.
esults and discussion
The PA yield after freeze-drying was 16%, and the total ﬂavonoid
ontent, expressed as vitexin, was 0.67% ± 0.01. The plant mate-
ial employed contained a lower concentration of ﬂavonoids than
t was expected; accordingly the Brazilian Pharmacopoeia the P.
lata plant drug should present a minimum of 1% of ﬂavonoids
Farmacopeia Brasileira, 2010) for leaves only. Previous ﬂavonoidrmacognosia 25 (2015) 407–412 409
quantiﬁcations of aqueous and hydro-alcoholic extracts from P.
alata leaves also presented higher concentrations, such as 2.6% (De-
Paris et al., 2002) and 2.9% (Petry et al., 2001). However, values
of 0.47% and 0.39% were also reported for P. alata leaves extracts
(Müller et al., 2005).
P. alata is known to present saponins as major secondary
metabolites, different from other Passiﬂora species in which
ﬂavonoids are the main metabolites (Birk et al., 2005). The main
characteristic property of saponins is their ability to cause hemol-
ysis. When added to a suspension of blood, saponins produce
changes in erythrocyte membranes, causing hemoglobin to dif-
fuse into the surrounding medium. The hemolytic activity of plant
extracts containing saponins was  determined by comparison with
that of a reference saponin, which has its hemolytic activity estab-
lished at 1000 units per g (WHO, 2011). The obtained PA extract,
indicated the presence of saponins by the persisting foam produced,
when tested. The measured hemolytic activity was 32 units for PA,
using Saponin (Merck®) as reference. This activity was not very
high when compared with the reference substance, but the hemol-
ysis might be increased if an enriched saponin fraction is analyzed
(Yuldasheva et al., 2005; Rocha et al., 2012).
Encapsulated extract characterization
Encapsulated extract showed particle size (diameter) of
359.3 ± 21.5 nm with polydispersity index of 0.288 ± 0.062 and zeta
potential of −36.2 ± 6.1 mV.  Nanocapsules vehicle (same formula-
tion with no extract added) exhibited diameter of 259.7 ± 16.4 nm,
polydispersity index of 0.241 ± 0.060 and zeta potential of
−32.7 ± 7.7 mV  (results expressed by mean ± standard error).
Mayer (2005) reported that the optimum radii should be
between 100 and 500 nm.  Sinha et al. (2004) consider that diame-
ter may  range between 10 and 1000 nm.  Mora-Huertas et al. (2010)
reviewed parameters of polymeric nanocapsules and concluded
that there are no expected rules for zeta potential values, as it
depends on polymer chemical properties, stabilizing agents and
medium’s pH. In most cases values below −10 mV  are obtained
(generally between −25 and −30 mV). This is considered a predic-
tion for good stability due to a high energy barrier between the
particles.
Antioxidant activity
Antioxidants can prevent or slow the oxidative damage to
human body by scavenging reactive oxygen species (ROS). Super-
oxide and hydroxyl radicals are major contributors to oxidative
damage of gastric mucosa, and are involved in the complex
pathogenesis of ethanol induced mucosal lesions. Plant phenolics,
including ﬂavonoids, are examples of compounds that can reduce
the damages caused by ROS, resulting in gastroprotective proper-
ties (Priya et al., 2012).
Several assays have frequently been used to estimate antiox-
idant capacities of plant extracts, including DPPH scavenging
activity and the oxygen radical absorption capacity (ORAC). The
ORAC assay is considered more relevant because it utilizes a bio-
logically relevant radical source (Prior et al., 2003). The antioxidant
capacity of PA was measured by DPPH and ORAC, presenting an EC50
of 1061.2 ± 8.5 g/ml and 1076 ± 85 mol  Trolox/g, respectively. In
order to assess the PA antioxidant potential rutin was used as refer-
ence and presented an EC50 of 18.3 ± 0.9 g/ml in the DPPH assay,
while literature data of EC50 for some of the ﬂavonoids found in
P. alata varied from 290 to 1000 g/ml (Okawa et al., 2001). The
ORAC assay also indicated that the antioxidant potential of PA is
not high, since plant extracts considered with a promising activ-
ity in this assay presented values from 3000 to 8500 mol  Trolox/g
(Dudonné et al., 2009). Although the low antioxidant potential from
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Fig. 1. Assay 1: relative lesion area (RLA, in %) of HCl/ethanol-induced gastric lesions
(150 mmol/l HCl in 60% (v/v) ethanol) in rats, after intragastric administration. Each
column represents the mean ± SEM. n = 8. *p < 0.05; **p < 0.01. PA: Passiﬂora alata
extract (100, 200, 400 mg/kg); positive control: lansoprazole (30 mg/kg); negative
control: water.
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Fig. 2. Assay 2: relative lesion area (RLA, in %) of HCl/ethanol-induced gastric lesions
(300 mmol/l HCl in 60% (v/v) ethanol) in rats, after intragastric administration.
Each column represents the mean ± SEM. *p < 0.05; solvent partition of Passiﬂora10 A. Wasicky et al. / Revista Brasileir
A, the presence of ﬂavonoids in the crude extract might explain
he lower hemolytic activity found for the crude extract when com-
ared with the isolated saponins. It is known that some ﬂavonoids
nd their glycosides are effective antioxidants protecting human
ed blood cells from free radical-induced oxidative hemolysis (Dai
t al., 2006).
astroprotective activity
Hemorrhagic ethanol-induced ulcers show nonspeciﬁc mecha-
isms, acting over several homeostasis regulators. In a review about
aboratory ulcer models, Glavin and Szabo (1992) summarize some
actors involved in this kind of gastric mucosal injury. Among other
actors, we can mention a decrease of: gastric mucosal blood ﬂow,
ucus, glutathione (GSH) and prostaglandin production; and an
ncrease of: free radical generation, histamine release, ischemia
nd vascular permeability. Kawano and Tsuji (2000) reviewed
ndotelin-1 and nitric oxide (NO) roles on gastric ulcer, including
n ethanol-induced lesions, concluding that these substances are
ssential to the mucosal blood ﬂow balance. Ethanol stimulates
ndothelin-1 release from gastric vessels, resulting in vasocon-
triction by interacting with ETA receptors. This process disturbs
astric microcirculation, which contributes to lesion formation.
ndogenous nitric oxide has a vasodilator effect and reduces the
eneration of hemorrhagic lesions. Interactions between these two
ubstances are important to the regulation of local vascular tone.
wiecien´ et al. (2002) also found evidences that reactive oxygen
pecies (ROS) also play a major role in ethanol-induced lesions
ue to a decrease in the gastric blood ﬂow, increment of inﬂam-
atory changes (increase of IL-1 and TNF levels), as well as
eneration of ROS and decrease of superoxide dismutase activity
n gastric mucosa, leading to lipid peroxidation and consequently
xidative stress and tissue damage. Lansoprazole, used as posi-
ive control in the ethanol induced ulceration methodology, plays
n important role on various gastric ulcer mechanisms. Albeit its
ain activity is over proton pump, it also may  show several acid-
ndependent gastroprotective effects, as histamine-stimulated acid
ecretion inhibition; increase of blood ﬂow and NO production;
nhancement of bicarbonate secretion stimulated by acid; increase
f gastric mucus content, sulfhydril compounds and prostaglandin
evels; antioxidant and anti-inﬂammatory effects. This nonspeciﬁc
ehavior of lansoprazole could explain why it can inhibit ulcer
esions caused by nonspeciﬁc mechanisms of the employed harm-
ul agent (Satoh et al., 1989; Inatomi et al., 1991; Brunton, 2006;
atoh, 2013).
In order to evaluate which compound classes could present gas-
roprotective activity, PA was fractioned with increasing polarity
olvents (n-hexane, ethyl acetate and water). Previously, almost
ll biological assays performed with P. alata used aqueous or
ydroethanol extracts (Petry et al., 2001; Noriega et al., 2011;
olomeu et al., 2014). Hexane fraction generally contains mostly
atty acids, pigments, phytosterols and terpenes (Harborne, 1978).
n P. alata ethyl acetate fraction, simple phenolic compounds and
on-glycoside ﬂavonoids were previously found (Vasic´ et al., 2012).
. alata aqueous fraction is known to contain the most polar com-
ounds, saponins and C-glycoside ﬂavonoids (Reginatto et al., 2001;
oyama et al., 2005). As the gastroprotective activity was lower in
he fractions it indicates that the activity observed was not caused
y one speciﬁc metabolite group.
In assay 1 (Fig. 1), using the necrotizing agent at 150 mmol/l,
A was able to inhibit completely the ulcer formation (compared
o the negative control) for all tested dosages, while lansoprazole
30 mg/kg) promoted 77% of inhibition. These results showed sig-
iﬁcant gastroprotective effect for PA in the model of acute gastric
lcer induced by HCl/ethanol. After the acute antiulcer test, at the
ose of 150 mmol/l HCl the relative area of lesion was  4% for thealata extract: HEX: n-hexane fraction (100 mg/kg), n = 7; EAC: ethyl acetate frac-
tion (100 mg/kg), n = 9; AQU: aqueous fraction (100 mg/kg), n = 7; positive control:
lansoprazole (30 mg/kg), n = 8; negative control: water, n = 9.
water control group. The proposal was to increase the concen-
tration of the ulcerative agent (300 mmol/l HCl), to increase the
ulceration area for the negative control (8%), in order to verify if at
this concentration the extract and the fractions would still be able
to prevent the ulceration in the tested model. In this assay, PA frac-
tions reduced the ulcer formation in 57% (n-hexane), 34% (ethyl
acetate) and 72% (aqueous fraction) of lesion area at 100 mg/kg,
and lansoprazole (30 mg/kg) 47% (Fig. 2). The most active fraction
was the aqueous one exhibiting only 29% of ulcer formation. How-
ever, none of the fractions exhibited higher activity than the crude
extract; further experiments were only performed with PA.
Using the higher concentration of the necrotizing agent, even
lower PA dosages (50 and 100 mg/kg) were also able to inhibit
ulcer formation, a decrease of 27% and 84% of lesion area was
observed (Fig. 3, assay 3), the control drug had a similar perfor-
mance compared to the higher PA dosage (84%). In the same assay,
PA nanocapsules exhibited stronger activity with 55%, 94% and
90% inhibition for the respective doses of 25, 50 and 100 mg/kg
(Fig. 3). As there was  no signiﬁcant difference between nanoen-
capsulated 50 and 100 mg/kg dosages, it suggests a dose-response
curve slightly above these doses for this formulation on this model.
Concerning the anti-ulcer test with the extract (PA) incorporated
and not incorporated in nanoparticles, there is a signiﬁcant differ-
ence between nano and PA at 50 mg/kg, but not at the 100 mg/kg
dose. Analyzing the graphs, it is possible to see that the maximum
A. Wasicky et al. / Revista Brasileira de Farmacognosia 25 (2015) 407–412 411
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cig. 3. Assay 3: relative lesion area (RLA, in %) of HCl/ethanol-induced gastric lesio
olumn  represents the mean ± SEM. n = 8 (for water, n = 7). **p < 0.01; ***p < 0.001; 
nd  100: encapsulated PA (25, 50 and 100 mg/kg); positive control: lansoprazole (3
lcer protection occurred at 50 mg/kg with the nanoencapsulated
xtract. For this reason, we suggest approximately this dosage, for
uture studies for developing a gastroprotective formulation using
he P. alata nanoencapsulated extract.
Plant extracts containing ﬂavonoids can inhibit the proton pump
ctivity or increase the secretion of mucus and PGE2 (prostaglandin
2), what explains its gastroprotective activity. Gracioso et al.
2002), investigating the antiulcer activity of Turnera ulmifolia L.
howed that the active fraction presented C-glycosylated ﬂavones,
erived from apigenin and luteolin. Baggio et al. (2007) suggested
hat the ﬂavonoid-rich fraction of Maytenus ilicifolia Mart. ex Reis-
ek possess antiulcer activity. As the PA extract contained 0.67%
avonoids, most of them C-glycosides, these compounds might
ave some inﬂuence in the activity measured. Although ﬂavonoids
re known to present free radical scavenger activity, which might
ave a clinical application as antiulcer drugs (Yamaguchi et al.,
000), the low antioxidant activity measured in PA indicates that
his was not the main gastroprotection mechanism involved in the
esults observed.
Moreover, dried aqueous P. alata extracts are also known to con-
ain 0.8% (w/w) saponins (Reginatto et al., 2004); these metabolites
an also be involved in the gastroprotection once we determined
he presence of non-hemolytic saponins in PA. In literature, among
he pharmacologic activities described for saponins, we ﬁnd the
ntiulcer activity (Hostettmann and Marston, 1995). In fact, one
f the most knowledgeable antiulcerogenic crude drugs of this
etabolite class is liquorice (Hostettmann and Marston, 1995).
lthough along with glycyrrhizin, other groups of pharmacologi-
ally active substances are present in Glycyrrhiza glabra roots and
hizomes in which ﬂavonoids are included (Saitoh et al., 1976).
espite the historic use of this plant, contradictory results are found
n its pharmacological efﬁcacy (Isbrucker and Burdock, 2006).
oreover, gastroprotective effect of tea saponin (Camellia sinen-
is) on ethanol induced gastric mucosal lesions in rats, is more
otent than that of omeprazole, as observed by Morikawa et al.
2006).
Concluding, our results provide scientiﬁc evidence for the use of
. alata as a gastroprotective medicine, a disease that needs new and
ore effective drugs. It is also important to note the fact that P. alata
s included in Renisus, a list of medicinal plants, which research
nd development of derived products are of interest to the ofﬁ-
ial health system of Brazil. Furthermore, the nanoencapsulation00 mmol/l HCl in 60% (v/v) ethanol) in rats, after intragastric administration. Each
nanocapsules vehicle; PA: Passiﬂora alata extract (50 and 100 mg/kg); nano 25, 50
kg); negative control: water.
seems to be an effective technology to improve the activity of P.
alata extracts to produce a gastroprotective herbal product.
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